tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jim Birchenough, 85 are a BUY (66.41%), 39 are a HOLD (30.47%), 4 are a SELL (3.13%).
Analyst Jim Birchenough, currently employed at WELLS FARGO, carries an average stock price target met ratio of 63.8% that have a potential upside of 39.25% achieved within 283 days.
Jim Birchenough’s has documented 324 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RGLS, Regulus Therapeutics at 13-Mar-2024.
Analyst best performing recommendations are on INFI (INFINITY PHARMACEUTICALS).
The best stock recommendation documented was for BLCM (BELLICUM PHARMACEUTICALS) at 2/14/2020. The price target of $4 was fulfilled within 31 days with a profit of $6.42 (61.61%) receiving and performance score of 19.87.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$30
4 years 2 months 19 days ago
(01-Sep-2020)
2/8 (25%)
$14.76 (96.85%)
30
Hold
$20
$1.83 (10.07%)
$31
4 years 6 months 14 days ago
(06-May-2020)
2/4 (50%)
$0.93 (13.82%)
13
Hold
$24
$5.83 (32.09%)
$33
5 years 1 months 28 days ago
(23-Sep-2019)
4/5 (80%)
$5.96 (33.04%)
39
Hold
6 years 1 months 26 days ago
(25-Sep-2018)
2/2 (100%)
$1.2 (5.04%)
27
What Year was the first public recommendation made by Jim Birchenough?
